Evidence map›Paper›PMID 23478959›Full record

ArticleAntimicrobial agents and chemotherapy2013

Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin.

Cristina García-de-la-Mària, Juan M Pericas, Ana Del Río, Ximena Castañeda, Xavier Vila-Farrés, Yolanda Armero, Paula A Espinal, Carlos Cervera, Dolors Soy, Carlos Falces and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Rare Postoperative Pelvic Lymphocyst Infection byInternational medical case reports journal · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Membrane Phenotypic, Metabolic and Genotypic Adaptations ofAntibiotics (Basel, Switzerland) · 2023
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Development of High-Level Daptomycin Resistance inAntimicrobial agents and chemotherapy · 2021
    Article
  13. Article
  14. Evaluating the Rapid Emergence of Daptomycin Resistance inJournal of clinical microbiology · 2021
    Article
  15. Strain-Specific Adaptations ofAntibiotics (Basel, Switzerland) · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Cristina García-de-la-MàriaInfectious Diseases Service, University of Barcelona, Barcelona, Spain.
Juan M Pericas
Ana Del Río
Ximena Castañeda
Xavier Vila-Farrés
Yolanda Armero
Paula A Espinal
Carlos Cervera
Dolors Soy
Carlos Falces
Salvador Ninot
Manel Almela
Carlos A Mestres
Jose M Gatell
Jordi Vila
Asuncion Moreno
Francesc Marco
Jose M Miró
Hospital Clinic Experimental Endocarditis Study Group
Universitat de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of high-level daptomycin resistance (HLDR; MIC of ≥ 256 mg/liter) after exposure to daptomycin has recently been reported in viridans group streptococcus (VGS) isolates. Our study objectives were as follows: to know whether in vitro development of HLDR after exposure to daptomycin was common among clinical isolates of VGS and Streptococcus bovis; to determine whether HLDR also developed during the administration of daptomycin to treat experimental endocarditis caused by the daptomycin-susceptible, penicillin-resistant Streptococcus mitis strain S. mitis 351; and to establish whether combination with gentamicin prevented the development of HLDR in vitro and in vivo. In vitro studies were performed with 114 VGS strains (mitis group, 92; anginosus group, 10; mutans group, 8; and salivarius group, 4) and 54 Streptococcus bovis strains isolated from 168 consecutive patients with infective endocarditis diagnosed between 1995 and 2010. HLDR was only observed after 24 h of exposure to daptomycin in 27% of the mitis group, including 27% of S. mitis isolates, 47% of S. oralis isolates, and 13% of S. sanguis isolates. In our experimental model, HLDR was detected in 7/11 (63%) and 8/12 (67%) isolates recovered from vegetations after 48 h of daptomycin administered at 6 mg/kg of body weight/24 h and 10 mg/kg/24 h, respectively. In vitro, time-kill experiments showed that daptomycin plus gentamicin was bactericidal against S. mitis 351 at tested concentrations of 0.5 and 1 times the MIC and prevented the development of HLDR. In vivo, the addition of gentamicin at 1 mg/kg/8 h to both daptomycin arms prevented HLDR in 21 out of 23 (91%) rabbits. Daptomycin plus gentamicin was at least as effective as vancomycin plus gentamicin. In conclusion, HLDR develops rapidly and frequently in vitro and in vivo among mitis group streptococci. Combining daptomycin with gentamicin enhanced its activity and prevented the development of HLDR in most cases.

Indexed as

AnimalsAnti-Bacterial AgentsDaptomycinDrug Resistance, BacterialDrug SynergismDrug Therapy, CombinationEndocarditis, BacterialGentamicinsHumansMicrobial Sensitivity TestsRabbitsSpecies SpecificityStreptococcal InfectionsStreptococcus anginosusStreptococcus bovisStreptococcus mitisAnti-Bacterial AgentsDaptomycinGentamicinsVancomycin

Identifiers

PMID23478959
PMCPMC3632914
OpenAlexW2111068343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.